IME indications and phase of development
| Indication . | Phase of development . | Ongoing trials? . |
|---|---|---|
| MDS | Phase 2 (high risk), phase 3 (low risk) | Yes |
| MF | Phase 3 | Yes |
| ET | Phase 2 | No |
| MM | Phase 2, limited by clinical hold | No |
| AML | Phase 2 | Yes |
| Lymphoid malignancies | Planned | No |
| Indication . | Phase of development . | Ongoing trials? . |
|---|---|---|
| MDS | Phase 2 (high risk), phase 3 (low risk) | Yes |
| MF | Phase 3 | Yes |
| ET | Phase 2 | No |
| MM | Phase 2, limited by clinical hold | No |
| AML | Phase 2 | Yes |
| Lymphoid malignancies | Planned | No |
MM, multiple myeloma.